Literature DB >> 19162046

Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats.

Manuela Di Benedetto1, Chiara Cavina, Claudio D'Addario, Giorgia Leoni, Sanzio Candeletti, Brian M Cox, Patrizia Romualdi.   

Abstract

It has been suggested that the opioid-like neuropeptide nociceptin/orphanin FQ(N/OFQ) and its receptor (NOPr) may contribute to Parkinson's disease. Based on this idea, the aim of our study was to investigate the involvement of the N/OFQ-NOPr system in an animal model of Parkinson's disease and to evaluate if this neuropeptidergic system is acting through mechanisms involving glutamate and/or GABA. We injected the neurotoxins MPP+ or 6-OHDA into the cerebral ventricles and 10 days later measured N/OFQ and NOPr gene expression in caudate putamen (CP) and substantia nigra (SN), by RT-PCR. A large reduction in N/OFQ and NOPr mRNAs was observed in the CP of rat treated with either MPP+ or 6-OHDA, MPP+ being more effective than 6-OHDA. Both the neurotoxins induced an increase in N/OFQ gene expression in the SN, but only MPP+ evoked a significant down-regulation of NOPr in this area, showing a slight trend of reduction in 6-OHDA treated rats. Moreover, a reduction in the levels of glutamic acid decarboxylase (GAD65/67), an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory neurotransmitter y-aminobutyric acid (GABA), was also observed in the SN following 6-OHDA. These data suggest that DA modulates N/OFQ-NOPr system gene expression in SN and CP, strengthening the hypothesis that this neuropeptidergic system could be implicated in the mechanisms underlying Parkinson's disease. Our data might also suggest that the GABAergic system plays a role in the regulation of nigral function, although further studies are necessary to confirm this hypothesis. In agreement with previous studies, we also support the hypothesis of a potential value for NOP receptor antagonists to attenuate symptoms related to the degeneration of nigrostriatal dopaminergic pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162046      PMCID: PMC2680584          DOI: 10.1016/j.neuropharm.2008.12.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  40 in total

Review 1.  Parkinson's disease. First of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

Review 2.  Parkinson's disease. Second of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living.

Authors:  J M Gorell; C C Johnson; B A Rybicki; E L Peterson; R J Richardson
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

Review 5.  Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds.

Authors:  K F Tipton; T P Singer
Journal:  J Neurochem       Date:  1993-10       Impact factor: 5.372

6.  Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding.

Authors:  C R Neal; A Mansour; R Reinscheid; H P Nothacker; O Civelli; H Akil; S J Watson
Journal:  J Comp Neurol       Date:  1999-10-04       Impact factor: 3.215

7.  Genetics of Parkinson's disease.

Authors:  T Gasser
Journal:  Clin Genet       Date:  1998-10       Impact factor: 4.438

8.  Parkinson's disease, pesticides, and glutathione transferase polymorphisms.

Authors:  A Menegon; P G Board; A C Blackburn; G D Mellick; D G Le Couteur
Journal:  Lancet       Date:  1998-10-24       Impact factor: 79.321

9.  Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Authors:  Matteo Marti; Flora Mela; Carlo Veronesi; Remo Guerrini; Severo Salvadori; Mauro Federici; Nicola B Mercuri; Anna Rizzi; Gianfranco Franchi; Lorenzo Beani; Clementina Bianchi; Michele Morari
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

10.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.

Authors:  M G Kaplitt; P Leone; R J Samulski; X Xiao; D W Pfaff; K L O'Malley; M J During
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

View more
  7 in total

1.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

Review 2.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

3.  Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Authors:  M Marti; F Mela; M Budri; M Volta; D Malfacini; S Molinari; N T Zaveri; S Ronzoni; P Petrillo; G Calò; M Morari
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells.

Authors:  Hongrong Xie; Ming Chang; Xinyu Hu; Danping Wang; Mingxiu Tian; Guoyi Li; Huiyi Jiang; Ying Wang; Zhong Dong; Yuhua Zhang; Linsen Hu
Journal:  Neurol Sci       Date:  2010-06-19       Impact factor: 3.307

5.  MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.

Authors:  S Gouty; J M Brown; J Rosenberger; B M Cox
Journal:  Neuroscience       Date:  2010-04-22       Impact factor: 3.590

6.  Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Authors:  Ludovico Arcuri; Riccardo Viaro; Simone Bido; Francesco Longo; Mariangela Calcagno; Pierre-Olivier Fernagut; Nurulain T Zaveri; Girolamo Calò; Erwan Bezard; Michele Morari
Journal:  Neurobiol Dis       Date:  2016-01-22       Impact factor: 5.996

Review 7.  A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia.

Authors:  Muhammad Saad Khan; Isabelle Boileau; Nathan Kolla; Romina Mizrahi
Journal:  Transl Psychiatry       Date:  2018-02-02       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.